MAP4343 | MAP2 | CAS#511-26-2 | Neuroprotectant

MedKoo Cat#: 127940 | Name: MAP4343

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.

Chemical Structure

MAP4343

CAS#511-26-2

Theoretical Analysis

MedKoo Cat#: 127940

Name: MAP4343

CAS#: 511-26-2

Chemical Formula: C22H34O2

Exact Mass: 330.2559

Molecular Weight: 330.51

Elemental Analysis: C, 79.95; H, 10.37; O, 9.68

Price and Availability

Size	Price	Availability
50mg	USD 550.00	2 Weeks
100mg	USD 950.00	2 Weeks
1g	USD 4,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MAP4343; MAP 4343; MAP-4343

IUPAC/Chemical Name

1-((3S,8S,9S,10R,13S,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one

InChi Key

ZVGQOQHAMHMMNE-BIBIXIOVSA-N

InChi Code

InChI=1S/C22H34O2/c1-14(23)18-7-8-19-17-6-5-15-13-16(24-4)9-11-21(15,2)20(17)10-12-22(18,19)3/h5,16-20H,6-13H2,1-4H3/t16-,17-,18+,19-,20-,21-,22+/m0/s1

SMILES Code

C[C@@]1([C@H]2C(C)=O)[C@](CC2)([H])[C@@](CC=C(C3)[C@@]4(CC[C@@H]3OC)C)([H])[C@]4([H])CC1

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Biological target:

MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2)

In vitro activity:

The synthetic pregnenolone-derivative MAP4343 (3β-methoxy-pregnenolone) binds MAP-2 in vitro and increases its ability to stimulate tubulin assembly. Reference: Bianchi M, Baulieu EE. 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1713-8. doi: 10.1073/pnas.1121485109. Epub 2012 Jan 19. Erratum in: Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4708. PMID: 22307636; PMCID: PMC3277154.

In vivo activity:

MAP4343’s efficacy was assessed in vivo with the most commonly used thoracic spinal cord compression/contusion models in rats. In the three models used, the post-traumatic subcutaneous injection of MAP4343 significantly improved the recovery of locomotor function after spinal cord injury, as shown by an earlier and more complete recovery compared to vehicle-treated rats. Reference: Duchossoy Y, David S, Baulieu EE, Robel P. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66. doi: 10.1016/j.brainres.2011.05.065. Epub 2011 Jun 12. PMID: 21704982.

	Solvent	mg/mL	mM
Solubility
	DMSO	25.0	75.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 330.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1: Bianchi M, Baulieu EE. 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1713-8. doi: 10.1073/pnas.1121485109. Epub 2012 Jan 19. Erratum in: Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4708. PMID: 22307636; PMCID: PMC3277154. 2: Duchossoy Y, David S, Baulieu EE, Robel P. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66. doi: 10.1016/j.brainres.2011.05.065. Epub 2011 Jun 12. PMID: 21704982.

In vivo protocol:

1: Duchossoy Y, David S, Baulieu EE, Robel P. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66. doi: 10.1016/j.brainres.2011.05.065. Epub 2011 Jun 12. PMID: 21704982.